Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Shalini Chopra(University of California, San Francisco), Michael J. Evans(University of California, San Francisco)
Cited by 11
Related Papers
CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
|Clinical Cancer Research|2022|30
Profiling the Surfaceome Identifies Therapeutic Targets for Cells with Hyperactive mTORC1 Signaling
|Molecular & Cellular Proteomics|2019|14
674 Multi-omic single-cell assessment of castration-resistant prostate cancer patients receiving ¹ <sup>7</sup> <sup>7</sup> Lu-PSMA-617 and pembrolizumab shows timing of radioligand therapy alters immune response
|Regular and Young Investigator Award Abstracts|2025|0